The sale is small relative to market cap and follows a pattern of routine 10b5-1 plan sales. No material impact expected; monitor for any acceleration of insider selling or changes in officer holdings.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $25.82entry
- T+1 · 13d ago −38.23%α −39.88% · $15.95
- T+5 · 7d ago −38.50%α −37.91% · $15.88
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Christine Ring, an officer of Nurix Therapeutics, filed a Form 144 notice of intent to sell 5,786 shares of common stock, valued at approximately $284,134 based on the filing date price. The shares were acquired through the exercise of stock options on November 2, 2026, and the sale is planned for the same day. The filing also discloses prior 10b5-1 plan sales in August, September, and October 2026, indicating a pattern of routine insider selling.
Key Facts
- Christine Ring, an officer, filed Form 144 to sell 5,786 shares of common stock.
- Estimated sale value is $284,133.60 based on the filing date.
- Shares were acquired via exercise of stock options on November 2, 2026.
- Proposed sale date is November 2, 2026 (same day as filing).
- Prior 10b5-1 plan sales occurred in August, September, and October 2026, totaling approximately $665,580.
- The sale represents about 0.26% of the issuer's outstanding shares (based on 109,249,814 shares outstanding).
- Market cap is $3.0 billion, making the sale value ~0.0095% of market cap.
Financial Impact
Sale of 5,786 shares valued at $284,134, representing 0.26% of outstanding shares and 0.0095% of market cap.
Risk Factors
- Insider selling could signal lack of confidence if it deviates from the established 10b5-1 pattern.
- The filing is an intent to sell; the actual sale may not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010564 |
| Document: 0001950047-26-010564-index.html | 0001950047-26-010564 |
| Document: 0001950047-26-010564.txt | 0001950047-26-010564 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $14.67 Now $14.73 +0.41% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers